Treatment of depression in first episode of schizophrenia: Results from EUFEST

[1]  J. Olivares,et al.  Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. , 2012, Comprehensive psychiatry.

[2]  H. Jørgensen,et al.  Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial , 2011, BMC psychiatry.

[3]  H. Möller,et al.  Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale , 2011, Acta psychiatrica Scandinavica.

[4]  T. Barnes.  Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology , 2011, Journal of psychopharmacology.

[5]  I. Melle,et al.  Suicidality in first episode psychosis is associated with insight and negative beliefs about psychosis , 2010, Schizophrenia Research.

[6]  L. Citrome.  Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed , 2010, Postgraduate medicine.

[7]  R. Fosse,et al.  Suicidality before and in the early phases of first episode psychosis , 2010, Schizophrenia Research.

[8]  I. Melle,et al.  Depression and Depressive Symptoms in First Episode Psychosis , 2010, The Journal of nervous and mental disease.

[9]  S. Kennedy,et al.  Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials , 2009, Expert opinion on pharmacotherapy.

[10]  M. Birchwood,et al.  The evolution of depression and suicidality in first episode psychosis , 2009, Acta psychiatrica Scandinavica.

[11]  S. Leucht,et al.  Second-generation antipsychotics for schizophrenia: can we resolve the conflict? , 2009, Psychological Medicine.

[12]  Bryan L Roth,et al.  N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity , 2008, Neuropsychopharmacology.

[13]  H. Möller,et al.  Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response , 2008, Psychiatry Research.

[14]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[15]  S. Stahl,et al.  Stahl's essential psychopharmacology : neuroscientific basis and practical application , 2008 .

[16]  M. Thase.  Quetiapine monotherapy for bipolar depression , 2008, Neuropsychiatric disease and treatment.

[17]  V. Srihari,et al.  Atypical antipsychotics for people with both schizophrenia and depression. , 2008, The Cochrane database of systematic reviews.

[18]  J. Lieberman,et al.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. , 2008, The Journal of clinical psychiatry.

[19]  J. Klosterkötter,et al.  Basic symptoms in early psychotic and depressive disorders. , 2007, The British journal of psychiatry. Supplement.

[20]  Starla M. Weaver,et al.  Comorbid depressive symptoms in the developmental course of adolescent‐onset psychosis , 2007, Early intervention in psychiatry.

[21]  M. Povey,et al.  Reduced polypharmacy in patients enrolled in the electronic schizophrenia adherence registry (E-STAR) and treated with risperidone long-acting injection (RLAI) for 6 months , 2007, European psychiatry.

[22]  R. Emsley,et al.  The relationships between depression and remission in first-episode psychosis. , 2006, World psychiatry : official journal of the World Psychiatric Association.

[23]  É. Fakra,et al.  Intérêt des antidépresseurs chez le patient schizophrène présentant un syndrome dépressif , 2006 .

[24]  L. DeLisi.  The Katrina disaster and its lessons. , 2006, World psychiatry : official journal of the World Psychiatric Association.

[25]  R. Kahn,et al.  The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial , 2005, Schizophrenia Research.

[26]  G. Molenberghs,et al.  Models for Discrete Longitudinal Data , 2005 .

[27]  G. Trendler,et al.  Schizophrenia and depression: Challenging the paradigm of two separate diseases—A controlled study of schizophrenia, depression and healthy controls , 2005, Schizophrenia Research.

[28]  Matthias J. Müller,et al.  The Calgary Depression Rating Scale for schizophrenia in a healthy control group: psychometric properties and reference values. , 2005, Journal of affective disorders.

[29]  J. Calabrese,et al.  Atypical antipsychotics in bipolar depression: potential mechanisms of action. , 2005, The Journal of clinical psychiatry.

[30]  Hans-Jürgen Möller,et al.  Antipsychotic and antidepressive effects of second generation antipsychotics , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[31]  J. Krystal,et al.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. , 2004, Archives of general psychiatry.

[32]  R. Emsley,et al.  Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia , 2003, Journal of psychopharmacology.

[33]  A. Cardno,et al.  Antidepressants for the treatment of depression in people with schizophrenia: a systematic review , 2003, Psychological Medicine.

[34]  S. Cooper,et al.  A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia , 2003, Journal of psychopharmacology.

[35]  H. Möller,et al.  Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone , 2002, European Neuropsychopharmacology.

[36]  G. Molenberghs,et al.  Linear Mixed Models for Longitudinal Data , 2001 .

[37]  S. Hirsch,et al.  Depression in schizophrenia: recognition and management in the USA , 2001, Schizophrenia Research.

[38]  P. Chadwick,et al.  Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression. , 2000, The British journal of psychiatry : the journal of mental science.

[39]  C. Lançon,et al.  Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). , 2000, Journal of affective disorders.

[40]  D. Stein,et al.  Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. , 1999, The Journal of clinical psychiatry.

[41]  S. Potkin,et al.  Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.

[42]  J. Feighner,et al.  Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial , 1998, Psychopharmacology.

[43]  G. Tollefson,et al.  Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol , 1998, European Neuropsychopharmacology.

[44]  S. Stahl,et al.  Book Review: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd Edition , 1996 .

[45]  P. Hayward,et al.  Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.

[46]  J. Addington,et al.  Specificity of the Calgary Depression Scale for schizophrenics , 1994, Schizophrenia Research.

[47]  J. Addington,et al.  Assessing Depression in Schizophrenia: The Calgary Depression Scale , 1993, British Journal of Psychiatry.

[48]  J. Lieberman,et al.  Depression in first-episode schizophrenia. , 1993, The American journal of psychiatry.

[49]  D. Goff,et al.  Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. , 1990, The American journal of psychiatry.

[50]  J. H. Stephens,et al.  Prognostic factors in recovered and deteriorated schizophrenics. , 1966, The American journal of psychiatry.

[51]  J. Lieberman,et al.  Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. , 2011, The Journal of clinical psychiatry.

[52]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[53]  A. Caputi,et al.  Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients , 1994, International clinical psychopharmacology.

[54]  P. Plasky,et al.  Antidepressant usage in schizophrenia. , 1991, Schizophrenia bulletin.

[55]  M. Goldman,et al.  Adjunctive fluoxetine improves global function in chronic schizophrenia. , 1990, The Journal of neuropsychiatry and clinical neurosciences.

[56]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.